Skip to main content
Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc. — Investor Relations & Filings

Ticker · RNAC ISIN · US8162121045 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2016-06-17 Regulatory Filings
Country US United States of America
Listing US RNAC

About Cartesian Therapeutics, Inc.

https://www.cartesiantherapeutics.com/

Cartesian Therapeutics, Inc. is a clinical-stage company that pioneers the development of mRNA-engineered cell therapies. The company's primary focus is on creating treatments for autoimmune diseases. Leveraging its novel mRNA technology platform, Cartesian develops therapeutic cells designed to target the drivers of these conditions. This approach aims to expand the reach and potential of cell therapy for patients with various autoimmune disorders. The company's lead asset, Descartes-08, is a central component of its clinical pipeline.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 for Selecta Biosciences Inc's proposed initial public offering. It requests acceleration of the effectiveness of the Registration Statement and mentions distribution of the Preliminary Prospectus. The content is related to the IPO process and regulatory compliance, specifically concerning the registration and offering of securities. This is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to the registration and offering process. The document length is short and it is a formal correspondence with the SEC, fitting the category of Regulatory Filings (RNS).
2016-06-17 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Selecta Biosciences, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references regulatory rules under the Securities Act of 1933 and discusses procedural matters related to the filing's effectiveness. The document does not contain financial statements, management discussion, or detailed report content. It is a regulatory communication related to a filing process rather than a financial report or announcement of results. The document length is short (2443 characters), and it is primarily a formal request letter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory correspondence and procedural filings that do not fit other categories.
2016-06-17 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter dated June 10, 2016, from legal counsel to the SEC staff in response to comments on a Registration Statement on Form S-1 filed by Selecta Biosciences, Inc. The letter addresses specific SEC staff comments regarding the company's disclosures, including management's discussion and analysis, critical accounting policies, and clinical trial data. The document references Amendment No. 1 to the Registration Statement and discusses detailed clinical trial data and financial statement notes. The presence of the Form S-1 registration statement and the nature of the document as a comment response letter to the SEC staff indicates this is a regulatory filing related to an IPO registration process. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or other specific report type. The document is a regulatory correspondence filing with the SEC, which fits best under Regulatory Filings (RNS). The document length is over 14,000 characters, so it is not a brief announcement or report publication notice. It is not a certification letter but a substantive response to SEC comments. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-06-10 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock on NASDAQ and references the related S-1 registration statement. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration. The document length is 3596 characters, which is relatively short and consistent with a regulatory filing form. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-06-08 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated June 8, 2016, for Selecta Biosciences, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings or other securities offerings. The text includes details about the offering, underwriting, and registration fee calculation. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to the company's fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content about the offering, not just an announcement or certification, so it is not RPA or RNS.
2016-06-08 English
Regulatory Filings 2016
Regulatory Filings
2016-06-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.